Maxim Group analyst Naz Rahman maintained a Buy rating on Silexion Therapeutics yesterday and set a price target of $24.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Naz Rahman has given his Buy rating due to a combination of factors including the promising preclinical data for Silexion Therapeutics’ SIL-204. The data shows that SIL-204 has demonstrated significant anti-tumor activity across multiple KRAS mutated cancer types, which include pancreatic, colorectal, and non-small cell lung cancers. This broad spectrum of efficacy supports the potential for SIL-204 to address a large market opportunity.
Moreover, Silexion’s strategic plans to initiate Phase 2/3 trials in the near future further bolster confidence in the stock. The company is preparing to engage with regulators in Israel and Europe to finalize the study design, aiming to start trials in the first half of 2026. With the clinical batches already manufactured and undergoing stability testing, the pathway to clinical trials appears well-structured, enhancing the investment appeal of Silexion’s stock.